Although some pioneer studies reported some potential biomarkers, such as exosomal miR-126 in CLL, exosomal IGF-1R and TGF-β1 in AML, the real clinical utilities of these biomarkers are waiting for validation in large, perspective clinical trials. Here, IGF1R is linked to B-cell chronic lymphocytic leukemia.